All News

The Food and Drug Administration has approved Tagrisso plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.

The Food and Drug Administration approved Amtagvi, a TIL therapy, for patients with advanced melanoma whose disease progressed on or after a checkpoint inhibitor and targeted therapy.

Treatment paradigms may soon be shifting in head and neck cancer, as recent research indicates that lower doses of chemoradiotherapy may be appropriate for some patients.

Even though conquering cancer scared me, I knew being courageous would help me with the fight.

From International Childhood Cancer Day to an Ivory Coast soccer player making a victorious comeback after testicular cancer, here’s what is happening in the oncology space this week.

Spending a fourth of my life as a cancer survivor, I’ve learned a few lessons along the way.

Dr. Inderjit Mehmi and Dr. Omid Hamid from the Angeles Clinic, explain how therapies like targeted therapies, immunotherapy and T-cell therapies are improving outcomes for patients with advanced melanoma.

The Food and Drug Administration approved Tepmetko for adults with metastatic non-small cell lung cancer with MET exon 14 skipping alterations.

Moderna and Merck have initiated V940-001, a phase 3 study evaluating vaccine mRNA-4157 and anti-PD-1 therapy Keytruda as postsurgical treatment for stage 2B to 4 melanoma.

After a while, I stopped caring about wearing a mastectomy bra and did was what comfortable to me: wearing a regular bra.

“Sleep apnea assessment must be a part of routine risk assessment for patients undergoing cancer therapeutics,” one researcher stated.

Treatment with immunotherapy demonstrated positive results regarding survival in patients with two types of soft-tissue sarcomas, research found.

The Food and Drug Administration will review Augtyro for potential approval in children and adults with advanced solid cancers that harbor NTRK gene fusions.

Survivors who were more physically active may experience less pain than survivors who were not as physically active, research found.

When I was finally allowed to eat after my mastectomy, the hospital-grade turkey sandwich tasted like the best thing ever.

Patients with myeloproliferative neoplasms should keep their care team up to date on any symptoms they’re experiencing, an expert said.

I wondered how much I could contribute to cholangiocarcinoma awareness, but determined that if I help just one person, then that's a success.

Concurrent circulating tumor DNA and tissue-based testing identified more patients eligible for personalized cancer care than either of the tests done alone.

I was in disbelief when I was diagnosed with cancer, but then I turned my attention to crafting my surviving strategies.

The Food and Drug Administration has approved Onivyde with oxaliplatin, fluorouracil and leucovorin, for the first-line treatment of patients with metastatic pancreatic adenocarcinoma, the agency has announced.

When people tell me I "fought cancer," I disagree. I believe I endured cancer.

The Food and Drug Administration has granted a Fast Track designation to the novel immune activator drug BXCL701 in combination with a checkpoint inhibitor for patients with metastatic small cell neuroendocrine prostate cancer (SCNC).

Patients with MPNs who are JAK2V617F- and CALR-positive had different bacterial compositions compared with people without MPNs, research found.

Here is what I would say to King Charles III after his recent cancer diagnosis.

The novel drug BMX-001 showed improved survival in certain patients with high-grade glioma and reduced cognitive decline caused by radiation therapy.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

After cancer, I finally went on a cruise and allowed myself to fight through my fears, which felt so freeing.

Researchers have initiated a phase 2 trial assessing a novel tyrosine kinase inhibitor that can potentially penetrate the central nervous system in patients with ALK-positive non-small cell lung cancer and other solid tumors.

Anktiva boosted responses to BCG treatment without affecting quality of life, research showed.

At a cancer support group at my church, we sit together and share our cancer stories.